An observational study in Childhood Tumor and Congenital Disorders, sponsored by The Wellcome Sanger Institute. Status unknown at 1 site in United Kingdom. Per ClinicalTrials.gov, last updated 2024-09-05.
Sponsored by The Wellcome Sanger Institute · Observational
Every cell and every organ in the human body derives from a fertilised egg. As the fertilised egg divides, a human being develops and grows. The process of how the fertilised egg divides and forms a human being is very sophisticated and is directed by the genetic information, the DNA, that is present in every cell.
When errors, mutations, in the DNA code arise, the orderly process of human development can be disrupted. This can lead to the development of tumours during childhood and congenital diseases (that is, abnormalities that children are born with).
The aim of this study is to define exactly which DNA errors underpin childhood tumours and congenital diseases.
Cancers and some congenital anomalies are caused by changes (mutations) in the genetic code (DNA) of cells. The use of Next Generation Sequencing (NGS) has enabled the study of the genetic changes that underpin these diseases, genome wide and at base pair resolution.
A key question about the molecular pathogenesis of a range of childhood tumours and congenital anomalies that remains unanswered is the order in which the different mutations arise. To define the order in which mutations arise, the investigators will need to reconstruct the life history of individual tumours / anomalies. This can be achieved by segregating the major clone ('ancestral' cell) from sub-clones or by studying multiple areas from the same lesion. Although this approach allows timing of mutations to some degree, in childhood tumours and congenital lesions this approach is fundamentally limited by the inability to define embryonic mutations. The basis of the limitation is that the lesions in question is conventionally compared to the patient's germline (the genetic information they have from birth). In such a comparison embryonic mutations will be misclassified as either germline or somatic (acquired).
To overcome this limitation one would have to compare the lesion to the parental germline.
Thus, here this study proposes to perform the first NGS study of childhood tumours and congenital anomalies, focusing on defining the embryonic pathogenesis. A unique feature of this study will be that lesions will be compared to the parental germline to define embryonic mutations. A focus of the analysis will be to define order in which mutations arise.
9,617 studies on the registry are indexed under Neoplasms; 2,508 are open to participants now.
This study's planned enrollment of 600 is above the median of 204 across 1,745 observational studies indexed under Neoplasms.
Browse Neoplasms studies →The Wellcome Sanger Institute is the lead sponsor of 10 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Participants will have either a tumour or congenital anomaly. The investigators aim to also recruit the participant's biological parents. In some cases, the participant's sibling(s) and close relatives may also be recruited into the study. Where post-mortem material will be accessed, the participant will have been enrolled in the study whilst alive.
Potential participants will be identified by participating NHS clinicians on an ongoing basis and from registers of patients internal to each participating NHS unit.
Surplus samples will be identified by participating NHS clinicians. Some samples may also be obtained through Biobanks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The participant identified to have a tumour or congenital condition (a condition from birth) that is likely to be due to errors of the genetic code (DNA).
Other: sample collection · Other: Seeking consent and assent
parents, siblings or close relatives of the participant with the tumour or congenital condition.
Other: sample collection · Other: Seeking consent and assent
Surplus material from surgery. New or stored blood or saliva. Semen (from adult males).
Consent or assent from all participants to be included in the study. Consent from parent / guardian for inclusion of children in study (as primary participant or relative/sibling, as applicable).
Description of the genetic mutations of each tumour and congenital anomaly.
For each tumour a catalogue of mutations will be derived from sequencing reads. The catalogues will be compared across tumour types / anomalies to identify the mutations that drive individual tumour types / anomalies. The life history of each tumour / anomaly will be determined. Methylation data will be analysed to derive a methylation profile for each tumour. The profiles of individual tumours will then be compared with each other to see whether tumour-type specific methylation profiles exist.
Time frame: 9.5 years
Plan to share: No — As is customary in the field, we will publish our anonymised data in research databases and archives. This includes EGA (European Genome-phenome Archive) where data will be made accessible via managed access to researchers or companies worldwide.
No publications or documents are linked to this record.
This study is status unknown, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Wellcome Sanger Institute